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Abstract
Background: Atrial fibrillation (AF) and chronic kidney disease (CKD) are known to increase the risk of stroke.
Objectives: We set out to examine the risk of stroke by kidney function and albuminuria in patients with and without AF.
Design: Retrospective cohort study.
Settings: Ontario, Canada.
Participants: A total of 736 666 individuals (>40 years) from 2002 to 2015.
Measurements: New-onset AF, albumin-to-creatinine ratio (ACR), and an estimated glomerular filtration rate (eGFR).
Methods: A total of 39 120 matched patients were examined for the risk of ischemic, hemorrhagic, or any stroke event, 
accounting for the competing risk of all-cause mortality. Interaction terms for combinations of ACR/eGFR and the outcome 
of stroke with and without AF were examined.
Results: In a total of 4086 (5.2%) strokes (86% ischemic), the presence of AF was associated with a 2-fold higher risk for any 
stroke event and its subtypes of ischemic and hemorrhagic stroke. Across eGFR levels, the risk of stroke was 2-fold higher 
with the presence of AF except for low levels of eGFR (eGFR < 30 mL/min/1.73 m2, hazard ratio [HR]: 1.38, 95% confidence 
interval [CI]: 0.99-1.92). Similarly across ACR levels, the risk of stroke was 2-fold higher except for high levels of albuminuria 
(ACR > 30 mg/g, HR: 1.61, 95% CI: 1.31-1.99). The adjusted risk of stroke with AF differed by combinations of ACR and 
eGFR categories (interaction P value = .04) compared with those without AF. Both stroke types were more common in 
patients with AF, and ischemic stroke rates differed significantly by eGFR and ACR categories.
Limitations: Medication information was not included.
Conclusions: Patients with CKD and AF are at a high risk of total, ischemic, and hemorrhagic strokes; the risk is highest 
with lower eGFR and higher ACR and differs based on eGFR and the degree of ACR.
Abrégé 
Contexte: La fibrillation auriculaire (FA) et l’insuffisance rénale chronique (IRC) augmentent le risque d’accident vasculaire 
cérébral (AVC).
Objectif: Nous voulions analyser le risque d’AVC selon la fonction rénale et l’albuminurie chez des patients atteints d’IRC 
avec ou sans FA.
Type d’étude: Étude de cohorte rétrospective.
Cadre: Ontario, Canada.
Sujets: Un total de 736 666 individus (>40 ans) entre 2002 et 2015.
Mesures: Les nouveaux cas de FA, le rapport albumine/créatinine urinaire (RAC) et le débit de filtration glomérulaire estimé 
(DFGe).
Méthodologie: Au total, 39 120 patients appariés ont été examinés pour le risque d’AVC ischémique, hémorragique 
ou autre, en tenant compte du risque concurrent de mortalité toutes causes confondues. Les effets d’interactions des 
combinaisons RAC/DFGe et de l’issue de l’AVC, avec ou sans FA, ont également été étudiés.
Résultats: Pour un total de 4 086 AVC (5,2 %), dont 86 % d’AVC ischémiques, la présence de FA était associée à un risque 
deux fois plus élevé de survenue d’un AVC et d’un de ses sous-types (ischémique et hémorragique). Pour l’ensemble des 
niveaux de DFGe, le risque d’AVC se révélait deux fois plus élevé en présence de FA, sauf pour les faibles valeurs de DFGe 
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(DFGe <30 mL/min/1,73 m2; RR: 1,38; IC 95 %: 0,99-1,92). De même, pour l’ensemble des niveaux de RAC, le risque d’AVC 
s’avérait deux fois plus élevé en présence de FA, à l’exception des patients présentant une albuminurie élevée (RAC >30 
mg/g; RR: 1,61; IC 95 %: 1,31-1,99). Le risque ajusté d’AVC avec FA différait selon les catégories de combinaisons RAC/DFGe 
(valeur de p de l’interaction: 0,04) lorsque comparé aux cas sans FA. Les deux types d’AVC se sont avérés plus fréquents 
chez les patients atteints de FA, et les taux d’AVC ischémiques différaient significativement selon les catégories de DFGe et 
de RAC.
Limites: Les renseignements sur la médication n’ont pas été inclus.
Conclusion: Les patients atteints d’IRC et de FA sont plus susceptibles de subir un AVC ischémique, hémorragique ou total. 
Ce risque s’avère encore plus élevé en présence d’un faible DFGe et d’un RAC élevé, et diffère selon les valeurs de DFGe 
et de RAC.
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What was known before
Atrial fibrillation (AF) is a well-recognized risk factor for 
stroke in patients with chronic kidney disease (CKD); how-
ever, the stroke risk associated with combinations of estimated 
glomerular filtration rate (eGFR) and albumin-to-creatinine 
ratio (ACR) both with and without AF is less clear.
What this adds
In this population-based administrative data study, a lower 
eGFR and a higher ACR were associated with a higher risk 
of stroke. The presence of AF conferred a roughly 2-fold 
higher risk of stroke across all eGFR and ACR categories.
Background
Chronic kidney disease (CKD) is defined as a reduction in 
glomerular filtration rate and/or proteinuria routinely mea-
sured by the albumin-to-creatinine ratio (ACR) and has a 
prevalence of 10% to 15% globally.1,2 Multiple cardiovascu-
lar diseases, including coronary artery disease, peripheral 
vascular disease, and stroke, are associated with CKD.3,4 
Atrial fibrillation (AF) is associated with an increased risk of 
stroke and is a common arrhythmia found in patients with 
CKD (event rate estimates range from 19 to 63 per 1000 
person-years).5-7
The association of AF and stroke in patients with advanced 
CKD presents a problematic clinical situation as there is lim-
ited evidence regarding the optimal role of anticoagulation 
for stroke prevention.8-13 Coupled with a high hemorrhage 
risk in patients with CKD and a high competing risk of mor-
tality, understanding the true risk of stroke in this population 
is of increased importance.14-16
The complex interactions between CKD, AF, and stroke 
have made it difficult to establish a clear understanding of 
how AF increases the risk of stroke in patients with CKD. 
The 2016 Kidney Disease Improved Global Outcomes 
(KDIGO) consensus conference on arrhythmias and CKD 
identified the need for further research characterizing the risk 
of AF-associated stroke in CKD across the spectrum of esti-
mated glomerular filtration rate (eGFR) and albuminuria.17 
Thus, we assessed the stroke risk by CKD stage in patients 
with and without AF, accounting for the competing risk of 
death. We hypothesized that both CKD stage and the pres-
ence of AF would significantly alter the risk of stroke.
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Methods
Design and Setting
We conducted a retrospective cohort study in Ontario, 
Canada using health care databases at the Institute for 
Clinical Evaluative Sciences (ICES). This study was con-
ducted using a prespecified protocol and reporting of the 
results adheres to the Reporting of Studies Conducted Using 
Observational Routinely-Collected Health Data (RECORD) 
guidelines (Supplementary Table 1).18 The use of data in this 
project was authorized under section 45 of Ontario’s Personal 
Health Information Protection Act, which does not require 
review by a research ethics board.
Data Sources
We ascertained patient characteristics, laboratory data, and 
outcome data from linked administrative databases. The 
Gamma-Dynacare database was used to obtain outpatient 
serum creatinine and ACR laboratory data. Gamma-Dynacare 
is a laboratory service provider that contains outpatient lab 
information for individuals who had blood work drawn at any 
of their 225 collection sites in Ontario. Demographics and 
vital status information were obtained from the Ontario 
Registered Persons Database. Diagnostic and procedural 
information from all hospitalizations was determined using 
the Canadian Institute for Health Information Discharge 
Abstract Database (CIHI-DAD). The CIHI National 
Ambulatory Care Reporting System (CIHI-NACRS) data-
base contains diagnostic information from all emergency 
department (ED) visits. Information was also obtained from 
the Ontario Health Insurance Plan (OHIP) database, which 
contains all health claims for inpatient and outpatient physi-
cian services. We identified patients with a history of kidney 
transplant or dialysis therapies (exclusion criteria) using the 
Canadian Organ Replacement Register. These datasets were 
linked using unique encoded identifiers and analyzed at ICES. 
Whenever possible, we defined patient characteristics and 
outcomes using validated codes (Supplementary Table 2).
Study Cohorts
The study cohort was accrued from April 1, 2002 to March 
31, 2012 (see Supplementary Figure 1). To be included, 
patients had to have 1 outpatient measure of urine ACR test 
and a serum creatinine measurement within 12 months of 
each other. For each patient, the date of the first eligible inci-
dent AF diagnosis was taken as the index date. We excluded 
patients <40 years of age due to the small sample size of 
younger individuals and those with a history of kidney trans-
plantation, dialysis, or stroke before their index date.
Exposure and Outcomes
Incident AF was defined by a single International Classification 
of Diseases (ICD) or billing code on first diagnosis during 
hospitalization, ED visit, or ambulatory care visit. The diag-
nosis of AF using ICD, OHIP, and NACRS has been previ-
ously validated with specificity and sensitivity >90%.19 To 
mimic a randomization process, unexposed individuals with-
out AF were assigned an index date based on the distribution 
of the index dates in the AF group such that there were no 
differences between the two. We further examined the effects 
of ACR and eGFR as continuous and categorical variables 
(ACR in mg/g: <3, 3-30, >30, and eGFR in mL/min/1.73 
m2: >90, 60-90, 45-59, 30-44, <30). A validation study of 
outpatient serum creatinine values found that most of the 
patients with a low eGFR had a similar or lower eGFR on 
repeat testing at least 30 days later.20 We used the Chronic 
Kidney Disease Epidemiology Collaboration equation to cal-
culate eGFR.21 The study outcomes were any incident stroke 
or subgroups of stroke type (ischemic or hemorrhagic). 
Ischemic stroke included transient ischemic events. 
Hemorrhagic strokes included intracranial or subarachnoid 
events. Hospitalization encounters with ischemic stroke and 
hemorrhagic events were identified using validated ICD 
codes, in CIHI-DAD and NACRS (Supplementary Table 2).22
Statistical Analysis
Patients were followed from their index date until the out-
come of interest, death, end-stage renal disease (defined as 
dialysis or kidney transplantation), or end of the study period 
(March 31, 2015). Known demographics and comorbid risk 
factors for stroke and stroke type were captured at the index 
date. We used standardized differences to compare baseline 
characteristics by AF status. Continuous variables are 
reported as medians (interquartile ranges [IQRs]) and cate-
gorical variables as numbers and percentages. Standardized 
differences describe differences between group means rela-
tive to the pooled standard deviation and are less sensitive to 
large sample sizes than traditional hypothesis testing.23 A dif-
ference > 10% is considered significant. We calculated the 
incidence rate using the cumulative incidence function for 
any stroke and stroke subtypes. We used propensity score 
matching followed by Fine and Grey subdistribution hazards 
model to examine the association of AF exposure and our 
outcomes.24 The following variables were included in the 
propensity score model: year of ACR, time from ACR to 
index date, sex (male referent), income quintile (lowest quin-
tile referent), location (rural vs urban), and comorbidities at 
baseline (diabetes mellitus, hypertension, myocardial infarc-
tion, congestive heart failure, major hemorrhage, coronary 
artery disease, coronary revascularization, peripheral artery 
disease, peripheral vascular disease, and chronic obstructive 
pulmonary disease). Individuals with AF were greedy 
matched 1:1 without replacement to non-AF individuals on 
the logit of the propensity score (±0.05), eGFR and ACR 
category. Fine and Grey models account for the competing 
risk of death and are especially useful in CKD studies where 
death is a common competing event.25,26 We estimated the 
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subdistribution hazard ratio (sHR) using regression model-
ing of the cumulative incidence function. To assess whether 
the stroke risk differed by the presence of AF and kidney 
function, a multiplicative interaction for AF × eGFR/ACR 
was examined. In this model, we created categories of all 
possible combinations (30 in total) of eGFR (>90, 60-90, 
45-59, 30-44, <30), ACR (<3, 3-30, >30), and AF (present/
absent). We conducted all analyses with SAS software, ver-
sion 9.4 (SAS Institute, Cary, NC, USA). Two-sided P values 
< .05 were treated as statistically significant.
Results
Baseline Characteristics
From a total cohort of 736 666 eligible patients from Ontario, 
Canada from 2002 to 2015, we identified 41 049 (5.6%) 
patients who developed incident AF from which 39 120 
(95.3%) were matched 1:1 with individuals without AF.
There were no statistical differences between those with 
and without AF after matching (Table 1). The average age 
was 74.9 (±10.6) years and 55.4% were male. The mean 
eGFR was 70.8 ± 20.7 mL/min/1.73 m2 and the median 
(IQR) ACR of 2 mg/g (1-5). Comorbid conditions were com-
mon among those with AF, with 27.5% having congestive 
heart failure, 42.1% having coronary artery disease, 60.6% 
having diabetes mellitus, and 82.1% having hypertension. 
This compared to those without AF in whom 25.6% had con-
gestive heart failure, 42.0% had coronary artery disease, 
62.2% had diabetes mellitus, and 83.4% had hypertension.
Association of AF With Stroke
A stroke event occurred in 5.2% (4086) of the study cohort 
(3519 ischemic [86%], 679 hemorrhagic [14%]) (Table 2) 
with a median (IQR) time to event of 4 (2-6) years from the 
first AF diagnosis. A stroke event was more common among 
those with AF (7.0% with AF, crude rate: 13.5, 95% 
Table 1. Baseline Characteristics of the Study Cohort by Atrial Fibrillation Status Among Propensity Score–Matched Patients.
Characteristics Total cohort (N = 78 240) Atrial fibrillation (N = 39 120) No atrial fibrillation (N = 39 120)
Age (mean, SD) 74.9 (10.6) 74.6 (10.5) 75.1 (10.6)
Men, n (%) 43 322 (55.4) 21 646 (55.3) 21 676 (55.4)
Income quintile, n (%)
 1 (low) 15 725 (20.1) 7802 (19.9) 7923 (20.3)
 2 17 149 (21.9) 8578 (21.9) 8571 (21.9)
 3 15 988 (20.4) 8016 (20.5) 7972 (20.4)
 4 15 068 (19.3) 7570 (19.4) 7498 (19.2)
 5 (high) 14 310 (18.3) 7154 (18.3) 7156 (18.3)
Urban residence, n (%) 70 415 (90.0) 35 187 (89.9) 35 228 (90.1)
Albumin-to-creatinine ratio (mg/g), 
median, (interquartile range)
1 (1-5) 2 (1-5) 2 (1-5)
 <3 51 482 (65.8%) 25 741 (65.8%) 25 741 (65.8%)
 3-30 21 460 (27.4%) 10 730 (27.4%) 10 730 (27.4%)
 >30 5298 (6.8%) 2649 (6.8%) 2649 (6.8%)
Estimated glomerular filtration rate (mL/
min/1.73 m2), mean (SD)
70.8 (20.7) 70.8 (20.8) 70.9 (20.6)
 >90 15 180 (19.4%) 7590 (19.4%) 7590 (19.4%)
 60-90 39 320 (50.3%) 19 660 (50.3%) 19 660 (50.3%)
 45-59 13 658 (17.5%) 6829 (17.5%) 6829 (17.5%)
 31-44 7696 (9.8%) 3848 (9.8%) 3848 (9.8%)
 ≤30 2386 (3.0%) 1193 (3.0%) 1193 (3.0%)
Comorbidities, n (%)
 Congestive heart failure 20 770 (26.5) 10 746 (27.5) 10 024 (25.6)
 Major hemorrhage 4738 (6.1) 2403 (6.1) 2335 (6.0)
 Myocardial infarction 4241 (5.4) 2123 (5.4) 2118 (5.4)
 Coronary artery disease 32 884 (42.0) 16 469 (42.1) 16 415 (42.0)
 Peripheral vascular disease 1812 (2.3) 894 (2.3) 918 (2.3)
 Coronary artery bypass grafting 1359 (1.7) 665 (1.7) 694 (1.8)
 Chronic obstructive pulmonary disease 4311 (5.5) 2186 (5.6) 2125 (5.4)
 Diabetes mellitus 48 078 (61.4) 23 726 (60.6) 24 352 (62.2)
 Hypertension 64 725 (82.7) 32 112 (82.1) 32 613 (83.4)
Note. All standardized differences were less than 10% between matched pairs (atrial fibrillation vs no atrial fibrillation) for all covariates listed.
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confidence interval [CI]: 11.3-15.9, vs 3.4% without AF, 
crude rate: 8.6, 95% CI: 6.5-11.0). The median (IQR) time to 
stroke was 4 (1-6) years in patients with AF compared with 5 
(3-7) years in those without AF. During the follow-up period, 
the total events of death and dialysis were 21 120 (27.0%) 
(AF—13 676 [35.0%], no AF—7444 [19.0%]) and 2888 
(3.7%) (AF—1974 [5.0%], no AF—914 [2.3%]), respec-
tively. Among those with AF, the sHRs for any stroke event, 
ischemic stroke, and hemorrhagic stroke were similar at 2.12 
(95% CI: 1.98-2.26), 2.14 (95% CI: 1.99-2.30), and 2.01 
(95% CI: 1.70-2.37), respectively, compared with those 
without AF.
Association of eGFR, AF, and Stroke
The stroke risk was consistent and approximately 2-fold 
higher within eGFR categories when comparing patients 
with and without AF (Supplementary Table 3). The relative 
risk was highest among those with eGFR of 60 to 90 mL/
min/1.73 m2 (sHR: 2.26, 95% CI: 2.06-2.48) and lowest for 
eGFR < 30 mL/min/1.73 m2 (sHR: 1.38, 95% CI: 0.99-
1.92). The absolute risk and number of events for stroke with 
AF were 7% (n = 1367) and 6.3% (n = 75) for eGFR of 60 
to 90 mL/min/1.73 m2 and eGFR < 30 mL/min/1.73 m2, 
respectively. For those without AF, the absolute risk and 
number of events for stroke were 3.2% (n = 623) and 4.8% 
(n = 57) for the eGFR values of 60 to 90 and <30.
Association of Albuminuria, AF, and Stroke
The stroke risk was consistently higher among those with AF 
compared with those without AF. The absolute stroke risk 
was higher at higher ACR levels among patients with and 
without AF (ACR < 3 mg/g: AF—6.1% and no AF—2.9%; 
ACR = 3-30 mg/g: AF—8.2% and no AF—4.1%; ACR > 
30 mg/g: AF—8.0% and no AF—5.4%). However, the rela-
tive stroke risk was higher with lower levels of ACR catego-
ries compared with no AF (ACR < 3 mg/g: sHR = 2.23, 
95% CI = 2.04-2.43; ACR = 3-30 mg/g: sHR = 2.09, 95% 
CI = 1.86-2.35; ACR > 30 mg/g: sHR = 1.61, 95% CI = 
1.31-1.99) (Supplementary Table 4).
Association of eGFR, Albuminuria, AF, and Stroke
The combined relative risk of stroke by eGFR, ACR, and AF 
status is presented in Table 3 and Supplementary Table 5. 
The stroke risk differed significantly by the presence of AF 
and combined categories of eGFR/ACR (P = .04). 
Compared with an eGFR > 90 mL/min/1.73 m2/ACR < 3 
mg/g and no AF, there was at least a 2-fold increase in the 
risk of stroke with AF. The stroke risk was consistently 
higher in patients with a lower eGFR level with and without 
AF. Among those with AF, the stroke risk increases in paral-
lel as the ACR increases (except for eGFR > 90 mL/
min/1.73 m2 and eGFR < 30 mL/min/1.73 m2), whereas in 
those without AF the stroke risk increases as ACR increases 
Table 2. Crude Counts, Event Rates With 95% CIs, and Type of Stroke Events by Atrial Fibrillation Status.
Atrial fibrillation No atrial fibrillation
 n (%) Cumulative incidence % (95% CI) sHR (95% CI) n (%) Cumulative incidence % (95% CI) sHR
All stroke events 2665 (6.80) 13.5 (11.27-15.93) 2.12 (1.98-2.26) 1316 (3.36) 8.6 (6.54-10.99) Ref
Ischemic stroke 2259 (5.77) 11.04 (8.91-13.42) 2.14 (1.99-2.30) 1104 (2.82) 4.38 (4.01-4.78) Ref
Hemorrhagic stroke 406 (1.04) 2.93 (1.95-4.21) 2.01 (1.70-2.37) 212 (0.54) 1.81 (0.83-3.49) Ref
Note. CI = confidence interval; sHR = subdistribution hazard ratio.
Table 3. The Hazard Ratio for Stroke by Atrial Fibrillation Status, eGFR and ACR Levels With eGFR > 90/ACR < 3 and Absence of 
Atrial Fibrillation as Referent.
eGFR/ACR
ACR < 3 ACR = 3-30 ACR > 30
No AF AF No AF AF No AF AF
>90 Ref 2.23 (1.78-2.79) 1.48 (1.06-2.06) 3.90 (3.02-5.04) 3.80 (2.52-5.72) 3.80 (2.47-5.83)
60-90 1.38 (1.12-1.71) 3.36 (2.76-4.11) 2.18 (1.73-2.74) 4.51 (3.65-5.56) 2.65 (1.88-3.72) 4.93 (3.70-6.58)
45-59 1.94 (1.53-2.49) 3.83 (3.07-4.77) 2.26 (1.71-2.99) 4.77 (3.76-6.05) 2.99 (2.02-4.43) 4.93 (3.52-6.91)
31-44 2.06 (1.55-2.75) 4.10 (3.20-5.24) 2.22 (1.61-3.06) 4.51 (3.45-5.88) 2.53 (1.60-3.99) 5.00 (3.47-7.18)
≤30 2.54 (1.60-4.04) 4.27 (2.91-6.28) 2.68 (1.71-4.21) 3.03 (1.96-4.69) 3.25 (1.83-5.76) 4.40 (2.58-7.51)
Note. The following variables were included in the propensity score model: year of ACR, time from ACR to index date, sex (male referent), income 
quintile (lowest quintile referent), location (rural vs urban), and comorbidities at baseline (diabetes mellitus, hypertension, myocardial infarction, 
congestive heart failure, major hemorrhage, coronary artery disease, coronary revascularization, peripheral artery disease, peripheral vascular disease, 
and chronic obstructive pulmonary disease). Individuals with AF were greedy matched 1:1 without replacement to non-AF individuals on the logit of the 
propensity score (±0.05), eGFR and ACR category. P value for the eGFR/ACR level × AF interaction is .04. eGFR = estimated glomerular filtration rate; 
ACR = albumin-to-creatinine ratio; AF = atrial fibrillation.
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in all eGFR categories. For high levels of albuminuria and 
normal kidney function, the stroke risk was similar for those 
with and without AF (sHR = 3.80 for both). The risk of 
stroke was 4.4-fold higher for those with a combination of 
an elevated ACR/lower eGFR with AF and 3-fold higher for 
those without AF.
Risk of Ischemic and Hemorrhagic Stroke by 
eGFR and ACR Level
Ischemic and hemorrhagic stroke were more common in 
patients with AF (event rate: ischemic/AF—11.04 [95% CI: 
8.91-13.42], ischemic/no AF—6.93 [95% CI: 5.17-9.04], 
hemorrhagic/AF—2.93 [95% CI: 1.95-4.21], hemorrhagic/
no AF—1.81 [95% CI: 0.83-3.49]) per 1000 person-years of 
follow-up. The proportion of ischemic strokes was higher 
with increasing ACR category (3.81% with ACR< 3 mg/g to 
5.98% with ACR > 30 mg/g). A similar rise was observed 
with declining eGFR, albeit with the proportion being rela-
tively similar from an eGFR ≤ 60 mL/min/1.73 m2. There 
were fewer hemorrhagic stroke events with no discernible 
difference in the crude risk by ACR or eGFR level among 
those with AF (AF ACR < 3 mg/g—0.89%, AF ACR > 30 
mg/g—0.94%).
Discussion
In this retrospective cohort of 39 120 matched patients, we 
found that the risk of stroke is associated with AF and that 
this risk differs significantly based on eGFR and ACR levels. 
The stroke risk was 4.4-fold higher with the combination of 
a low level of eGFR, an elevated ACR, and AF compared 
with those with normal kidney function and no AF. Even in 
the absence of AF, a low eGFR and a high ACR increased the 
stroke risk 3.3-fold compared with normal kidney function. 
We observed a remarkably consistent approximate 2-fold 
higher stroke risk with the presence of AF across most eGFR 
and ACR levels. One exception was among those with nor-
mal eGFR and high ACR, where the stroke was identical at 
3.8-fold higher for those with and without AF. Consistent 
with previous studies, we observed a higher stroke risk 
among those without AF with lower eGFR and higher ACR 
levels.8-10,15,27 Lastly, the higher stroke risk with AF was 
largely driven by ischemic stroke events with a little observed 
difference in hemorrhagic stroke types. Taken together, AF 
universally increases stroke risk in patients with CKD; how-
ever, the risk is modified considerably by eGFR and ACR.
Previous studies have examined the association of stroke, 
eGFR, and albuminuria with conflicting results. A meta-
analysis of 21 studies conducted by Lee et al found that 
patients with CKD (defined as eGFR < 60 mL/min/1.73 m2) 
had a 43% greater risk of stroke than patients with normal 
baseline eGFR.27 Subgroup analyses by eGFR level (>60, 
40-60, <40 mL/min/1.73 m2) demonstrated a dose-response 
relationship with an increased risk of stroke with worsening 
eGFR.
A post hoc analysis of ROCKET-AF reported that a reduc-
tion in eGFR of 10 mL/min/1.73 m2 was associated with a 
12% increase in the adjusted stroke risk.15 Fewer studies 
have compared the relative contributions of both eGFR and 
proteinuria on stroke risk. Go et al28 examined 10 908 
patients from the Anticoagulation and Risk Factors in Atrial 
Fibrillation (ATRIA) cohort reporting that both eGFR and 
proteinuria were independent risk factors for stroke in 
patients with AF. In contrast, Sandsmark et al29 reported that 
proteinuria, but not eGFR, was independently associated 
with stroke in 3939 patients with CKD from the Chronic 
Renal Insufficiency Cohort (CRIC). In our study, we found 
that both eGFR and albuminuria were independently associ-
ated with stroke risk in patients with AF, but the risks dif-
fered. The adjusted stroke risk by eGFR increased but 
plateaued once the eGFR was below 60 mL/min/1.73 m2, 
whereas it continually increased in a dose-dependent manner 
with increasing ACR level. This is consistent with and 
extends the findings reported in CRIC to patients with AF 
and suggests that albuminuria, as opposed to eGFR, plays a 
more significant role in determining stroke risk in more 
advanced CKD. Our study differed from previous studies as 
our cohort was population based (as opposed to referred and 
under the care of a nephrologist in CRIC), we had a large 
number of events (1781 strokes) allowing for detection of 
risk among eGFR/ACR categories, we accounted for the 
competing risk of death, and we performed propensity score 
matching to reduce residual confounding. Our study unifies 
and advances results from the literature examining the asso-
ciation of eGFR, ACR, and stroke suggesting that CKD 
increases the risk of stroke; however, this risk is considerably 
different depending on eGFR and ACR levels.
We found a consistent higher stroke risk across all levels 
of eGFR and proteinuria, both with and without AF, consis-
tent with previous literature.27 Across eGFR levels, the stroke 
risk with AF was 2- to 3.8-fold higher than that without AF. 
For ACR, the risk was 2- to 3.2-fold higher with AF across 
the strata of ACR. Interestingly, the difference in relative risk 
of stroke with AF was attenuated across lower eGFR and 
higher ACR levels. For example, the presence of AF confers 
a 3.8-fold increase in stroke risk at eGFR > 90 mL/min/1.73 
m2, whereas it confers a 2-fold increase with eGFR < 30 
mL/min/1.73 m2. This difference in risk is likely attributable 
to the increase in baseline risk of stroke in the non-AF group 
and the additional higher competing risk of death among 
those with low eGFR. For example, the proportion of strokes 
with no AF increases from 1.01% with eGFR > 90 mL/
min/1.73 m2 to 2.78% with eGFR < 30 mL/min/1.73 m2. 
This observation has potentially important clinical conse-
quences as the lower incremental stroke risk attributable to 
AF at low levels of eGFR may mitigate the benefits of anti-
coagulation, a question warranting further investigation.
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Most of the stroke events were ischemic (85%), as 
opposed to hemorrhagic strokes, and the crude proportion of 
ischemic strokes increased in a dose-dependent manner with 
lower eGFR and higher ACR. Despite creating our matched 
cohort from a large population (>700 000 individuals), we 
were unable to determine the adjusted risk of hemorrhagic 
stroke by eGFR and ACR levels. Previous studies have 
reported an association between proteinuria and hemorrhagic 
stroke risk, a finding we were unable to confirm.29,30
The role of anticoagulation in advanced CKD and AF for 
prevention of thromboembolism represents an area of 
uncertainty. At present, there are no randomized trials dem-
onstrating a reduction in ischemic stroke risk with antico-
agulation for CrCl < 25 mL/min.31-33 We previously 
reported the stroke risk for 1400 matched pairs of CKD 
(eGFR < 45) patients with AF with and without warfarin 
anticoagulation.8 We found no difference in ischemic stroke 
risk with baseline and time-varying warfarin use. Similar 
conflicting results have recently been reported in a primary 
care population of patients with advanced age in the United 
Kingdom.9 Emerging evidence with direct oral anticoagu-
lants (DOACs) seems to suggest a net clinical benefit in 
patients with lower eGFRs; however, definitive clinical tri-
als remain pending.34 As such, we did not include antico-
agulation in this study.
Our study did have limitations. Certain categories had 
relatively few events (175 hemorrhagic strokes in total, <80 
strokes with eGFR < 30 mL/min/1.73 m2). As our primary 
focus was the risk of AF in patients with CKD, we included 
all patients aged more than 40 in our cohort and did not have 
information regarding medications. Although we accounted 
for the competing risk of death in our models, we did not 
attempt to differentiate death due to stroke from other causes 
of death. This is due to unreliability in accurately determin-
ing the cause of death in administrative database studies.35 
We only used a single measure of eGFR and ACR to catego-
rize kidney function. We excluded individuals with a previ-
ous stroke and attempted to capture incident stroke events 
and as such our stroke risk of 1.3% per year likely represents 
an underestimate of the true stroke risk. Misclassification of 
hemorrhagic transformations with ischemic strokes may 
have occurred.
In this large population-based cohort study, we found that 
both eGFR and ACR were associated with and modified the 
stroke risk in patients with CKD. Atrial fibrillation was con-
sistently associated with a higher stroke risk across all eGFR 
and ACR levels. Furthermore, the risk is largely attributable 
to ischemic stroke events. Our findings aid in identifying 
individuals with a high stroke risk with CKD and underscore 
the importance of AF as an associated risk factor for stroke.
Authors’ Note
This work was presented as an oral abstract at the American Society 
of Nephrology Annual General Meeting on November 2017 in New 
Orleans, LA, USA. Parts of this material are based on data and/or 
information compiled and provided by CIHI. However, the analy-
ses, conclusions, opinions, and statements expressed in the material 
are those of the authors and not necessarily those of CIHI.
Acknowledgments
The authors thank Gamma-Dynacare for laboratory data and IMS 
Brogan Inc for use of their Drug Information Database.
Author Contributions 
M.M.S., A.B.E., and T.M.-B. contributed to the study design of the 
manuscript, which was reviewed and developed further by the rest 
of the authors. A.B.E. conducted the data analysis. T.M.-B. and 
M.M.S. drafted the first version of the manuscript. The remaining 
authors contributed to develop the manuscript draft to its final form.
Ethics Approval and Consent to Participate
The use of data in this project was authorized under section 45 of 
Ontario’s Personal Health Information Protection Act, which does 
not require review by a research ethics board.
Consent for Publication
All authors have given their consent for publication of this article.
Availability of Data and Materials
The data and materials are not available for this study.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest 
with respect to the research, authorship, and/or publication of this 
article: M.M.S. received investigator-initiated grant funding from 
Otsuka and CME symposium–related speaker fees from Astrazeneca.
Funding
The author(s) disclosed receipt of the following financial support 
for the research, authorship, and/or publication of this article: 
M.M.S. was supported by the Innovation Fund of the Alternative 
Funding Plan for the Academic Health Sciences Centers of Ontario. 
This study was supported by the Institute for Clinical Evaluative 
Sciences (ICES) Western and Ottawa site. ICES is funded by an 
annual grant from the Ontario Ministry of Health and Long-Term 
Care (MOHLTC). Core funding for ICES Western is provided by 
the Academic Medical Organization of Southwestern Ontario 
(AMOSO), the Schulich School of Medicine and Dentistry 
(SSMD), Western University, and the Lawson Health Research 
Institute (LHRI). The research was conducted by members of the 
ICES Kidney, Dialysis and Transplantation team, at the ICES 
Ottawa and Western facilities, who are supported by a grant from 
the Canadian Institutes of Health Research (CIHR). The opinions, 
results, and conclusions are those of the authors and are indepen-
dent from the funding sources. No endorsement by ICES, AMOSO, 
SSMD, LHRI, CIHR, or the MOHLTC is intended or should be 
inferred. Dr Manish M Sood is supported by the Jindal Research 
Chair for the Prevention of Kidney Disease. Drs N.N.L. and 
A.O.M. were both supported by KRESCENT New Investigator 
Awards. Dr J.-J.C. was supported by the Swedish Heart and Lung 
Foundation.
8 Canadian Journal of Kidney Health and Disease
ORCID iDs
Amber O. Molnar  https://orcid.org/0000-0003-4549-0202
Ngan N. Lam  https://orcid.org/0000-0002-0129-7091
Manish M. Sood  https://orcid.org/0000-0002-9146-2344
Supplemental Material
Supplemental material for this article is available online.
References
 1. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kid-
ney disease: global dimension and perspectives. Lancet. 
2013;382(9888):260-272.
 2. Carville S, Wonderling D, Stevens P on behalf of the Guideline 
Development Group. Early identification and management of 
chronic kidney disease in adults: summary of updated NICE 
guidance. BMJ. 2014;349:g4507.
 3. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and 
Stroke Statistics—2017 update: a report from the American 
Heart Association. Circulation. 2017;135(10):e146-e603.
 4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease 
as a risk factor for development of cardiovascular disease: a 
statement from the American Heart Association Councils 
on Kidney in Cardiovascular Disease, High Blood Pressure 
Research, Clinical Cardiology, and Epidemiology and 
Prevention. Circulation. 2003;108(17):2154-2169.
 5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an 
independent risk factor for stroke: the Framingham Study. 
Stroke. 1991;22(8):983-988. doi:10.1161/01.str.22.8.983.
 6. Dad T, Weiner DE. Stroke and chronic kidney disease: epide-
miology, pathogenesis, and management across kidney disease 
stages. Semin Nephrol. 2015;35(4):311-322. doi:10.1016/j.
semnephrol.2015.06.003.
 7. Keskar V, Sood MM. Use of oral anticoagulation in the management 
of atrial fibrillation in patients with ESRD: con. Clin J Am Soc 
Nephrol. 2016;11(11):2085-2092. doi:10.2215/CJN.03200316.
 8. Keskar V, McArthur E, Wald R, et al. The association of anti-
coagulation, ischemic stroke, and hemorrhage in elderly adults 
with chronic kidney disease and atrial fibrillation. Kidney Int. 
2017;91(4):928-936. doi:10.1016/j.kint.2016.10.017.
 9. Jun M, James MT, Manns BJ, et al. The association between 
kidney function and major bleeding in older adults with atrial 
fibrillation starting warfarin treatment: population based obser-
vational study. BMJ. 2015;350. doi:10.1136/bmj.h246.
 10. Bonde AN, Lip GYH, Kamper A-L, et al. Net clinical ben-
efit of antithrombotic therapy in patients with atrial fibrillation 
and chronic kidney disease: a nationwide observational cohort 
study. J Am Coll Cardiol. 2014;64(23):2471-2482.
 11. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update 
of the Canadian Cardiovascular Society atrial fibrillation guide-
lines: recommendations for stroke prevention and rate/rhythm 
control. Can J Cardiol. 2012;28(2):125-136. doi:10.1016/j.
cjca.2012.01.021.
 12. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused 
update of the Canadian Cardiovascular Society guidelines 
for the management of atrial fibrillation. Can J Cardiol. 
2014;30(10):1114-1130.
 13. Kumar S, de Lusignan S, McGovern A, et al. Ischaemic stroke, 
haemorrhage, and mortality in older patients with chronic kid-
ney disease newly started on anticoagulation for atrial fibril-
lation: a population based study from UK primary care. BMJ. 
2018;360. doi:10.1136/bmj.k342.
 14. Molnar AO, Bota SE, Garg AX, et al. The risk of major hem-
orrhage with CKD. J Am Soc Nephrol. 2016:27:2828-2832. 
doi:10.1681/ASN.2015050535.
 15. Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as 
a predictor of stroke and systemic embolism in patients with 
nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) 
index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct 
factor Xa inhibition Compared with vitamin K antagonism for 
prevention of stroke and Embolism Trial in Atrial Fibrillation) 
and ATRIA (AnTicoagulation and Risk factors In Atrial fibril-
lation) study cohorts. Circulation. 2013;127(2):224-232.
 16. Lutz J, Menke J, Sollinger D, Schinzel H, Thurmel K. 
Haemostasis in chronic kidney disease. Nephrol Dial 
Transplant. 2014;29(1):29-40. doi:10.1093/ndt/gft209.
 17. Turakhia MP, Blankestijn PJ, Carrero J-J, et al. Chronic kid-
ney disease and arrhythmias: conclusions from a Kidney 
Disease: Improving Global Outcomes (KDIGO) Controversies 
Conference. Eur Heart J. 2018:2314-2325. doi:10.1093/eur-
heartj/ehy060.
 18. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting 
of studies Conducted using Observational Routinely-
collected health Data (RECORD) Statement. PLoS Med. 
2015;12(10):e1001885.
 19. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, 
Dublin S. Identifying atrial fibrillation from electronic medi-
cal data: a systematic review. Pharmacoepidemiol Drug Saf. 
2012;21(1):141-147.
 20. Garg AX, Mamdani M, Juurlink DN, van Walraven C. 
Identifying individuals with a reduced GFR using ambula-
tory laboratory database surveillance. J Am Soc Nephrol. 
2005;16(5):1433-1439. doi:10.1681/ASN.2004080697.
 21. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison 
of risk prediction using the CKD-EPI equation and the MDRD 
study equation for estimated glomerular filtration rate. JAMA. 
2012;307(18):1941-1951. doi:10.1001/jama.2012.3954.
 22. Andrade SE, Harrold LR, Tjia J, et al. A systematic review of vali-
dated methods for identifying cerebrovascular accident or transient 
ischemic attack using administrative data. Pharmacoepidemiology 
and Drug Safety. 2012;21(suppl 1):100-128.
 23. Austin PC. Using the standardized difference to compare the 
prevalence of a binary variable between two groups in observa-
tional research. Comm Stat Simulat Comput. 2009;38(6):1228-
1234.
 24. Dehejia RH, Wahba S. Propensity score-matching meth-
ods for nonexperimental causal studies. Rev Econ Stat. 
2002;84(1):151-161.
 25. Fine JP, Gray RJ. A proportional hazards model for the sub-
distribution of a competing risk. J Am Stat Assoc. 1999;94 
(446):496-509.
 26. Hsu JY, Roy JA, Xie D, et al. Statistical methods for cohort 
studies of CKD: survival analysis in the setting of com-
peting risks. Clin J Am Soc Nephrol. 2017. doi:10.2215/
CJN.10301016.
Mace-Brickman et al 9
 27. Lee M, Saver JL, Chang K-H, Liao H-W, Chang S-C, 
Ovbiagele B. Low glomerular filtration rate and risk of stroke: 
meta-analysis. BMJ. 2010;341. doi:10.1136/bmj.c4249.
 28. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and 
glomerular filtration rate on risk of thromboembolism in atrial 
fibrillation: the Anticoagulation and Risk Factors in Atrial 
Fibrillation (ATRIA) study. Circulation. 2009;119(10):1363-
1369.
 29. Sandsmark DK, Messé SR, Zhang X, et al. Proteinuria, but not 
eGFR, predicts stroke risk in chronic kidney disease: Chronic 
Renal Insufficiency Cohort study. Stroke. 2015;46(8):2075-
2080.
 30. Mahmoodi BK, Yatsuya H, Matsushita K, et al. Association 
of kidney disease measures with ischemic versus hemor-
rhagic strokes: pooled analyses of 4 prospective community-
based cohorts. Stroke. 2014;45(7):1925-1931. doi:10.1161/
STROKEAHA.114.004900.
 31. Rodriguez-Yanez M, Castellanos M, Blanco M, et al. Micro- 
and macroalbuminuria predict hemorrhagic transformation 
in acute ischemic stroke. Neurology. 2006;67(7):1172-1177. 
doi:10.1212/01.wnl.0000238353.89194.08.
 32. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus 
warfarin in nonvalvular atrial fibrillation. New Engl J Med. 
2011;365(10):883-891.
 33. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus 
warfarin in patients with atrial fibrillation. New Engl J Med. 
2009;361(12):1139-1151.
 34. Ha JT, Neuen BL, Cheng LP, et al. Benefits and harms of oral 
anticoagulant therapy in chronic kidney disease: a systematic 
review and meta-analysis. Ann Intern Med. 2019;171(3):181-
189. doi:10.7326/M19-0087.
 35. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban 
versus warfarin in patients with atrial fibrillation. New Engl J 
Med. 2011;365(11):981-992.
